Ambrosia Biosciences Inc., named after the drink of the Greek gods, secured a $100 million series B to advance its preclinical pipeline of oral obesity drugs. The startup formed after Pfizer Inc.

Renovare Therapeutics, Inc., a privately-held biotechnology company pioneering regenerative therapeutics for osteoarthritis, today announced its formal launch from stealth mode and collaboration with ...

Old Dog, New Tricks: Oxybutynin for the Treatment of Androgen Deprivation Therapy–Related Vasomotor Symptoms Presented at ASCO Annual Meeting, virtual, May 29-31, 2020; World Congress on Lung Cancer, ...

Presented at ASCO Annual Meeting, virtual, May 29-31, 2020; World Congress on Lung Cancer, virtual, January 28-31, 2021; ASCO Annual Meeting, virtual, June 4-8, 2021 ...

"Section 232" national security levies won't apply to a wide array of drugs, meaning the "overall threat to the sector should ...

In this interview, Dr. Michelle Fraser highlights how base editing and AI-designed enzymes are expanding therapeutic ...

The funding, which ranks as one of the largest of its kind for a China-based drug startup, will support a portfolio of ...

Consultant and author Ram Charan talks to Matthew Partridge about how China corners the global market in a wide array of sectors by exploiting foreign companies ...

An updated edition of the Feb. 20, 2026, article. Genomics involves a thorough study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). It involves understanding how genes ...

On a conference call with analysts, Gilead walked through how a string of recent deals focused on cancer and autoimmune ...

Lunsekimig, a bispecific drug aimed at two popular targets, succeeded in studies in asthma and nasal polyps but missed its mark in an eczema trial.

Get all latest & breaking news on Galena Biopharma. Watch videos, top stories and articles on Galena Biopharma at moneycontrol.com.